AU2003212268B2 - Pharmaceutical composition of a PDE4 or PDE3/4 inhibitor and a histamine receptor antagonist - Google Patents

Pharmaceutical composition of a PDE4 or PDE3/4 inhibitor and a histamine receptor antagonist Download PDF

Info

Publication number
AU2003212268B2
AU2003212268B2 AU2003212268A AU2003212268A AU2003212268B2 AU 2003212268 B2 AU2003212268 B2 AU 2003212268B2 AU 2003212268 A AU2003212268 A AU 2003212268A AU 2003212268 A AU2003212268 A AU 2003212268A AU 2003212268 B2 AU2003212268 B2 AU 2003212268B2
Authority
AU
Australia
Prior art keywords
inn
tetrahydro
active ingredient
pharmaceutically acceptable
phthalazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003212268A
Other languages
English (en)
Other versions
AU2003212268A1 (en
Inventor
Rolf Beume
Daniela Bundschuh
Christian Weimar
Stefan-Lutz Wollin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of AU2003212268A1 publication Critical patent/AU2003212268A1/en
Assigned to NYCOMED GMBH reassignment NYCOMED GMBH Request for Assignment Assignors: ALTANA PHARMA AG
Application granted granted Critical
Publication of AU2003212268B2 publication Critical patent/AU2003212268B2/en
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: NYCOMED GMBH
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: TAKEDA GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2003212268A 2002-03-06 2003-02-25 Pharmaceutical composition of a PDE4 or PDE3/4 inhibitor and a histamine receptor antagonist Ceased AU2003212268B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06
EP02004987.0 2002-03-06
PCT/EP2003/001876 WO2003074055A1 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Publications (2)

Publication Number Publication Date
AU2003212268A1 AU2003212268A1 (en) 2003-09-16
AU2003212268B2 true AU2003212268B2 (en) 2008-09-11

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003212268A Ceased AU2003212268B2 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a PDE4 or PDE3/4 inhibitor and a histamine receptor antagonist

Country Status (32)

Country Link
US (1) US20050112069A1 (ru)
EP (2) EP1849468B1 (ru)
JP (1) JP5150034B2 (ru)
KR (1) KR20040095255A (ru)
CN (1) CN101257904A (ru)
AR (1) AR038858A1 (ru)
AT (1) ATE369134T1 (ru)
AU (1) AU2003212268B2 (ru)
BR (1) BR0308220A (ru)
CA (1) CA2478612C (ru)
CO (1) CO5611148A2 (ru)
CY (2) CY1106927T1 (ru)
DE (1) DE60315426T2 (ru)
DK (2) DK1482938T3 (ru)
EA (2) EA010886B1 (ru)
ES (2) ES2291618T3 (ru)
HK (1) HK1071308A1 (ru)
HR (1) HRP20040909B1 (ru)
IL (1) IL163336A (ru)
IS (2) IS2536B (ru)
MX (1) MXPA04008460A (ru)
NO (1) NO335254B1 (ru)
NZ (1) NZ535611A (ru)
PL (1) PL211574B1 (ru)
PT (2) PT1849468E (ru)
RS (1) RS51018B (ru)
SG (1) SG160197A1 (ru)
SI (2) SI1849468T1 (ru)
TW (1) TWI347845B (ru)
UA (1) UA80117C2 (ru)
WO (1) WO2003074055A1 (ru)
ZA (1) ZA200407104B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1956906A4 (en) * 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
DE602007005167D1 (de) * 2006-12-20 2010-04-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor-antagonisten
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
ME02598B (me) 2011-02-07 2017-06-20 Scipharm Sarl Nova kompozicija za lečenje cistične fibroze
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
JP2017525721A (ja) * 2014-08-26 2017-09-07 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
SG11201702900SA (en) 2014-10-09 2017-05-30 Guangdong Zhongsheng Pharmaceutical Co Ltd Hydroxyl purine compounds and applications thereof
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962464A (en) * 1997-02-11 1999-10-05 Sepracor Inc. Methods and compositions for treating allergic asthma using descarboethoxyloratadine
EP1005865A1 (en) * 1998-11-10 2000-06-07 Panacea Biotec Limited A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine
WO2001030777A1 (en) * 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
AU687087B2 (en) * 1993-07-02 1998-02-19 Takeda Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962464A (en) * 1997-02-11 1999-10-05 Sepracor Inc. Methods and compositions for treating allergic asthma using descarboethoxyloratadine
EP1005865A1 (en) * 1998-11-10 2000-06-07 Panacea Biotec Limited A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine
WO2001030777A1 (en) * 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Andri L et al. Allergie et Immunologie 1992 Vol. 24(8) pp313-314, 317-319 *
Hatzelmann A et al. J, Pharmacol. Exp. Therapeut. 2001 Vol. 297(1) pp267-279 *

Also Published As

Publication number Publication date
PL371056A1 (en) 2005-06-13
IS7438A (is) 2004-09-03
CY1113894T1 (el) 2016-07-27
EP1482938A1 (en) 2004-12-08
UA80117C2 (ru) 2007-08-27
EA200401137A1 (ru) 2005-04-28
PT1482938E (pt) 2007-11-15
SI1849468T1 (sl) 2013-03-29
ES2400670T3 (es) 2013-04-11
NZ535611A (en) 2006-03-31
CY1106927T1 (el) 2012-09-26
DE60315426T2 (de) 2008-07-03
US20050112069A1 (en) 2005-05-26
CO5611148A2 (es) 2006-02-28
WO2003074055A1 (en) 2003-09-12
EA007903B1 (ru) 2007-02-27
EP1849468B1 (en) 2012-12-05
KR20040095255A (ko) 2004-11-12
EA200601592A1 (ru) 2006-12-29
SI1482938T1 (sl) 2007-12-31
TW200306855A (en) 2003-12-01
CA2478612A1 (en) 2003-09-12
DK1849468T3 (da) 2013-02-04
DE60315426D1 (de) 2007-09-20
AR038858A1 (es) 2005-01-26
CA2478612C (en) 2013-12-10
EP1849468A3 (en) 2007-11-07
CN101257904A (zh) 2008-09-03
SG160197A1 (en) 2010-04-29
EP1849468A2 (en) 2007-10-31
IS8760A (is) 2008-09-04
ATE369134T1 (de) 2007-08-15
JP2005524666A (ja) 2005-08-18
DK1482938T3 (da) 2007-12-03
EA010886B1 (ru) 2008-12-30
RS78004A (en) 2006-12-15
HRP20040909B1 (en) 2012-11-30
RS51018B (sr) 2010-10-31
EP1482938B1 (en) 2007-08-08
TWI347845B (en) 2011-09-01
NO20044230L (no) 2004-12-06
ZA200407104B (en) 2006-12-27
ES2291618T3 (es) 2008-03-01
IL163336A (en) 2009-02-11
PT1849468E (pt) 2013-02-27
NO335254B1 (no) 2014-10-27
AU2003212268A1 (en) 2003-09-16
IS2536B (is) 2009-08-15
PL211574B1 (pl) 2012-05-31
MXPA04008460A (es) 2004-12-06
JP5150034B2 (ja) 2013-02-20
HRP20040909A2 (en) 2005-08-31
HK1071308A1 (en) 2005-07-15
BR0308220A (pt) 2005-01-04

Similar Documents

Publication Publication Date Title
US20220226332A1 (en) Phosphodiesterase Inhibitor Treatment
AU2003212268B2 (en) Pharmaceutical composition of a PDE4 or PDE3/4 inhibitor and a histamine receptor antagonist
KR100782091B1 (ko) 배변을 촉진하는 의약 조성물
EP2903619B1 (en) Phosphodiesterase inhibitors for treating taste and smell disorders
TW201028422A (en) Amino-heterocyclic compounds
TWI222867B (en) Pharmaceutical compositions for treating hepatitis virus infections n-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds
US10555940B2 (en) Phosphodiesterase inhibitor treatment
JP2001302547A (ja) 女性の性機能不全を処置するための組成物および方法
IL166483A (en) Pharmaceuticals containing ciclasonide and antihistamine
TW200423932A (en) Combination of a PDE IV inhibitor and a TNF-alpha antagonist
CN1972913A (zh) 四氢吡喃基环戊基四氢吡啶并吡啶趋化因子受体活性调节剂
US20180221406A1 (en) Therapeutic combinations of antiviral and anti-inflammatory therapies
ES2228512T3 (es) Combinacion sinergica que comprende roflumilast y un inhibidor de pde-3.
AU2004269923A1 (en) Use of PDE4 inhibitors for the treatment of diabetes mellitus
WO2023034466A1 (en) Cgrp antagonists for treating psoriasis
JP2003063988A (ja) Ｐｄｅ阻害剤を有効成分として含有する脊髄小脳変性症治療剤

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: NYCOMED GMBH

Free format text: FORMER NAME: ALTANA PHARMA AG

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ TAKEDA GMBH .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired